Performance improvement company Biome Analytics has announced the publication of a study in Circulation: Cardiovascular Quality and Outcomes, resulting from its collaboration with researchers at University of California, San Francisco (San Francisco, USA) and Cedars Sinai Medical Center (Los Angeles, USA)
The study—Implementation of an electronic health records safe contrast limit tool for prediction of contrast-associated acute kidney injury and reduction in contrast use after percutaneous coronary intervention—assesses the effectiveness of an electronic health records (EHR) safe contrast limit tool in predicting acute kidney injury (AKI) risk and reducing contrast use for patients undergoing percutaneous coronary intervention (PCI).
Rakan Khaki, chief operating officer at Biome Analytics and an author of the study, said: “We are honoured to collaborate with the esteemed researchers on this important study, which shows the impacts of implementing a pragmatic risk model in an EHR to predict AKI and reduce contrast for PCI patients. We look forward to continuing to develop novel solutions to advance Biome’s commitment to improving the quality care of cardiovascular care.”
The study found that the EHR safe contrast limit tool was able to predict AKI with an accuracy of 64.1% and was associated with a small decrease in contrast use during PCI but no change in AKI rates. Biome Analytics assisted with data curation and analysis.
Source CardiovascularNews
Duc Tin Clinic
Tin tức liên quan
Performance diagnostique de l’interféron gamma dans l’identification de l’origine tuberculeuse des pleurésies exsudatives
A Mixed Phenotype of Airway Wall Thickening and Emphysema Is Associated with Dyspnea and Hospitalization for Chronic Obstructive Pulmonary Disease.
Radiological Approach to Asthma and COPD-The Role of Computed Tomography.
Significant annual cost savings found with UrgoStart in UK and Germany
Thrombolex announces 510(k) clearance of Bashir catheter systems for thromboembolic disorders
Phone: (028) 3981 2678
Mobile: 0903 839 878 - 0909 384 389